Advertisement

Vaccines and Other Biologicals

  • Sudhi Ranjan Garg
Chapter

Abstract

Louise Pasteur prepared the first crude nerve tissue vaccine for rabies. Dr. David Semple developed the completely inactivated and safer Semple vaccine at Central Research Institute in Kasauli (India). With the advent of modern cell culture vaccines, the WHO does not advocate the use of the earlier nerve tissue vaccines anymore. Modern vaccines produced on various cellular substrates and continuous cell lines are highly effective in both pre-exposure and postexposure prophylaxis against rabies. Different novel vaccines such as attenuated rabies mutants, viral recombinant vaccines, DNA vaccines, and subunit vaccines have been developed recently that hold great promise for the future. The use of rabies immunoglobulin (RIG) for passive immunisation also dates back to the nineteenth century. Currently two types of products, namely, equine RIG and human RIG, are available. Development of alternative products and MAb is underway. There has also been considerable progress in the production of rabies vaccines for animal use. Several types of vaccines are available for administration to domestic animals or wild species by parenteral or oral routes. A third generation of live veterinary rabies vaccine has been developed more recently using recombinant technology.

Keywords

Rabies Virus Continuous Cell Line Rabies Vaccine Rabies Virus Glycoprotein Rabies Virus Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Anonymous (2010) New treatment for rabies advances after successful phase 1 trial in India. Science Daily, 14 Sept 2010. http://www.sciencedaily.com/releases/2010/09/100914121501.htm. Accessed 5 July 2012
  2. Anonymous (2012) Rabies antibody combination. Crucell. http://www.crucell.com/R_and_D-Clinical_Development-Rabies_Antibody_Product. Accessed 11 June 2012
  3. APCRI (2009) Manual on rabies immunoglobulin (RIG) administration, 1st edn. Association for Prevention and Control of Rabies in India, BangaloreGoogle Scholar
  4. Bonito RF, de Oliveira NM, Nishioka Sde A (2004) Adverse reactions associated with a Fuenzalida-Palacios rabies vaccine: a quasiexperimental study. Rev Soc Bras Med Trop 37:7–9PubMedCrossRefGoogle Scholar
  5. Cliquet F (2012) Oral vaccines used for rabies control programmes: types, storage, quality control and performance in different species. European Commission. http://ec.europa.eu/food/animal/diseases/eradication/rabies_pres_19.pdf. Accessed 18 June 2012
  6. Cliquet F, Robardet E, Must K, Laine M, Peik K, Picard-Meyer E, Guiot AL, Niin E (2012) Eliminating rabies in Estonia. PLoS Negl Trop Dis 6(2):e1535. doi: 10.1371/journal.pntd.0001535 PubMedCrossRefGoogle Scholar
  7. Ertl HCJ (2009) Novel vaccines to human rabies. PLoS Negl Trop Dis 3(9):e515. doi: 10.1371/journal.pntd.0000515 PubMedCrossRefGoogle Scholar
  8. Fehlner-Gardiner C, Rudd R, Donovan D, Slate D, Kempf L, Badcock J (2012) Comparing ONRAB® and RABORAL V-RG® oral rabies vaccine field performance in raccoons and striped skunks, New Brunswick, Canada, and Maine, USA. J Wildl Dis 48(1):157–167PubMedCrossRefGoogle Scholar
  9. Fernandes A, Kaundinya JO, Daftary G, Saxena L, Banerjee S, Pattnaik P (2008) Chromatographic purification of equine immunoglobulin G F(ab)2 from plasma. J Chromatogr B 876:109–115CrossRefGoogle Scholar
  10. Fox JP, Koprowski H, Conwell DP, Black J, Gelfand HM (1957) Study of antirabies immunization of man. Observations with HEP Flury and other vaccines, with and without hyperimmune serum, in primary and recall immunizations. Bull WHO 17:869–904PubMedGoogle Scholar
  11. Fuenzalida E, Palacios R, Borgono JM (1964) Antirabies antibody responses in man to vaccine made from infected suckling-mouse brains. Bull WHO 30:431–436PubMedGoogle Scholar
  12. Hicks DJ, Fooks AR, Johnson N (2012) Developments in rabies vaccines. Clin Exp Immunol. doi:10.1111/j.1365‐2249.2012.04592.xPubMedGoogle Scholar
  13. Kittipongwarakarn S, Hawe A, Tantipolphan R, Limsuwun K, Khomvilai S, Puttipipatkhachorn S, Jiskoot W (2011) New method to produce equine antirabies immunoglobulin F(ab')2 fragments from crude plasma in high quality and yield. Eur J Pharm Biopharm 78:189–195PubMedCrossRefGoogle Scholar
  14. Koprowski L, Cox HR (1948) Studies on chick embryo adapted rabies virus: I Culture characteristics and pathogenicity. J Immunol 60:533–554PubMedGoogle Scholar
  15. Lafay F, Benejean J, Tuffereau C, Flamand A, Coulon P (1994) Vaccination against rabies: construction and characterization of SAG2, a double avirulent derivative of SADBern. Vaccine 12:317–320PubMedCrossRefGoogle Scholar
  16. Leach CN, Johnson HN (1940) Human rabies, with special reference to virus distribution and titer. Am J Trop Med Hyg 20:335–340Google Scholar
  17. Mahendra BJ, Madhusudana SN, Sampath G, Datta SS, Ashwathnarayana DH, Venkatesh GM, Sudarshan MK, Bilugumba G, Shamanna M (2010) Immunogenicity, safety and tolerance of a purified duck embryo vaccine (PDEV, VAXIRAB) for rabies post-exposure prophylaxis – results of a multicentric study in India. Hum Vaccine 6(9):721–724CrossRefGoogle Scholar
  18. McGettigan JP (2010) Experimental rabies vaccines for humans. Expert Rev Vaccines 9:1177–1186. doi: 10.1586/erv.10.105 PubMedCrossRefGoogle Scholar
  19. Müller T, Dietzschold B, Ertl H, Fooks AR, Freuling C, Fehlner-Gardiner C, Kliemt J, Meslin FX, Rupprecht CE, Tordo N, Wanderler AI, Kieny MP (2009) Deve-lopment of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis 3(11):e542. doi: 10.1371/journal.pntd.0000542 PubMedCrossRefGoogle Scholar
  20. Nandi S, Kumar M (2010) Development in immunoprophylaxis against rabies for animals and humans. Avicenna J Med Biotechnol 2(1):3–21PubMedGoogle Scholar
  21. Peck FB, Powell HM, Culbertson CG (1955) A new antirabies vaccine for human use. Appl Microbiol 45:679–683Google Scholar
  22. Ramya R, Mohana Subramanian B, Sivakumar V, Senthilkumar RL, Sambasiva Rao KRS, Srinivasan VA (2011) Expression and solubilization of insect cell-based rabies virus glycoprotein and assessment of its immunogenicity and protective efficacy in mice. Clin Vaccine Immunol 18:1673–1679. doi: 10.1128/CVI.05258-11 PubMedCrossRefGoogle Scholar
  23. Rosatte R (2011) Evolution of wildlife rabies control tactics. Adv Virus Res 79:397–419PubMedCrossRefGoogle Scholar
  24. Semple D (1911) The preparation of a safe and efficient antirabic vaccine. Sci Mem Med Sanit Dept India 44:1–31Google Scholar
  25. Steck F, Wandeler A, Bischel P, Hafliger U, Schneider L (1982) Oral immunisation of foxes against rabies. Laboratory and field studies. Comp Immunol Microbiol Infect Dis 5:165–171PubMedCrossRefGoogle Scholar
  26. Sveshnikov PG, Yagudin TA, Morozkina EV, Klyachko EV, Zatsepin SS, Benevolensky SV, Shemchukova OB, Pozdnyakova LP, Solopova ON (2010) Production of a humanized Fab fragment of a neutralizing antibody against rabies virus. Moscow Univ Chem Bull 65:154–158. doi: 10.3103/S0027131410030090 CrossRefGoogle Scholar
  27. Ullas PT, Desai A, Madhusudana SN (2012) Rabies DNA vaccines: current status and future. World J Vaccines 2:36–45. doi: 10.4236/wjv.2012.21005 CrossRefGoogle Scholar
  28. Vodopija I, Clarke HF (1991) Human vaccination against rabies. In: Baer GM (ed) The natural history of rabies, 2nd edn. CRC Press, Boca Raton, pp 571–595Google Scholar
  29. WHO (1981) Requirements for rabies vaccine for human use. WHO Expert Committee on Biological Standardization. Thirty-first report. WHO technical report series, no. 658, Annex 2. World Health Organization, GenevaGoogle Scholar
  30. WHO (1987) Requirements for rabies vaccine (inactivated) for human use produced in continuous cell lines. WHO Expert Committee on Biological Standardization. Thirty-seventh report. WHO technical report series, no. 760. World Health Organization, GenevaGoogle Scholar
  31. WHO (1994a) Requirements for rabies vaccine for human use. WHO Expert Committee on Biological Standardization. Forty-third report. WHO technical report series, no. 840, Annex 4. World Health Organization, GenevaGoogle Scholar
  32. WHO (1994b) Requirements for rabies vaccine (inactivated) for human use produced in continuous cell lines. WHO Expert Committee on Biological Standardization. Forty-third report. WHO technical report series, no. 840, Annex 5. World Health Organization, GenevaGoogle Scholar
  33. WHO (2007) Recommendations for inactivated rabies vaccine for human use produced in cell substrates and embryonated eggs. WHO Expert Committee on Biological Standardization. Fifty-sixth report. WHO technical report series, no. 941, Annex 2. World Health Organization, GenevaGoogle Scholar
  34. WHO (2010) Rabies vaccines: WHO position paper. Wkly Epidemiol Rec No 32 85:309–320Google Scholar
  35. WHO (2012) Rabies. World Health Organization. www.who.int. Accessed 10 Mar 2012
  36. WHO SEARO (2012) Rabies: Country profile: India. World Health Organization, Regional Office for South-East Asia, New Delhi. http://www.searo.who.int/LinkFiles/Zoonoses_IND-rabies-cp.pdf. Accessed 15 Aug 2012
  37. Wu X, Franka R, Henderson H, Rupprecht CE (2011a) Live attenuated rabies virus co-infected with street rabies virus protects animals against rabies. Vaccine 29:4195–4201PubMedCrossRefGoogle Scholar
  38. Wu X, Smith TG, Rupprecht CE (2011b) From brain passage to cell adaptation: the road of human rabies vaccine development. Expert Rev Vaccines 10:1597–1608PubMedCrossRefGoogle Scholar

Copyright information

© Springer India 2014

Authors and Affiliations

  • Sudhi Ranjan Garg
    • 1
  1. 1.Veterinary Public Health & EpidemiologyLala Lajpat Rai University of Veterinary and Animal SciencesHisarIndia

Personalised recommendations